Loading cancer entity…
Loading cancer entity…
Clinical trials
35 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06376084 | Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC(FOREFRONT) | active not recruiting | — | 532 | AstraZenecaINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06971848 | Evaluation of Skin Tests in Biotherapy Allergies(ETCABIO) | recruiting | N/A | 70 | University Hospital, AngersOTHER_GOV | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06494241 | Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study | active not recruiting | — | 1,000 | AstraZenecaINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03684486 | Rehabilitation by Effort for Patients With Advanced Bronchial Cancer(RehabKBP) | terminated | N/A | 19 | University Hospital, ToulouseOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04222972 | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)(AcceleRET-Lung) | terminated | Phase 3 | 223 | Hoffmann-La RocheINDUSTRY | 22 | Mar 5, 2026 | clinicaltrials |
| NCT06841874 | Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC(Tale EAP) | no longer available | — | — | Nuvation Bio Inc.INDUSTRY | 0 | Dec 24, 2025 | clinicaltrials |
| NCT03786653 | Feasibility of Immunotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting (ImHADom)(ImHADom) | completed | — | 10 | RENAULT Patrick AldoOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors(ARROW) | completed | Phase 1 / Phase 2 | 590 | Hoffmann-La RocheINDUSTRY | 13 | May 31, 2025 | clinicaltrials |
| NCT04862780 | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | terminated | Phase 1 | 177 | Blueprint Medicines CorporationINDUSTRY | 10 | Feb 10, 2025 | clinicaltrials |
| NCT05241873 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | terminated | Phase 1 | 103 | Blueprint Medicines CorporationINDUSTRY | 5 | Feb 10, 2025 | clinicaltrials |
| NCT06564870 | Efficacy and Safety Study of DURVALUMAB Maintenance in Patients With Stage III Non-Small Cell Lung Cancer(DURVABREIZH) | unknown | — | 200 | University Hospital, BrestOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT04802902 | Feasibility of Immunotherapy Plus Chemotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting(CombHADom) | completed | — | 10 | Centre Hospitalier de PAUOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06177925 | A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC | recruiting | Phase 2 | 62 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05605236 | Stereotactic Margins in Localized Bronchial Cancer (T1/T2a, N0)(Stereotactic) | completed | — | 300 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT04989283 | Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05153408 | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | terminated | Phase 1 | 20 | Blueprint Medicines CorporationINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03085069 | A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC | unknown | Phase 2 | 146 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 16, 2023 | clinicaltrials |
| NCT03328559 | Kinetics of Circulating Tumoral Cells in Bronchial Primitive Cancer | completed | N/A | 6 | Fondation Hôpital Saint-JosephOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT04697446 | External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC | unknown | — | 279 | Blueprint Medicines CorporationINDUSTRY | 3 | Aug 10, 2021 | clinicaltrials |
| NCT03402048 | The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial(EPIC) | unknown | Phase 3 | 567 | University of Turin, ItalyOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT04517019 | Randomised Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Radiotherapy(OnkoFit II) | unknown | N/A | 201 | University Hospital TuebingenOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT03134872 | A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC | completed | Phase 3 | 419 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 9, 2020 | clinicaltrials |
| NCT03331588 | Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer | completed | Phase 3 | 200 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Mar 2, 2020 | clinicaltrials |
| NCT00652769 | A New Pathway With BronchOscopic or Oesophageal Ultrasound for Lung Cancer Diagnosis and STaging (BOOST)(BOOST) | completed | Phase 3 | 168 | University College London HospitalsOTHER | 1 | Nov 1, 2017 | clinicaltrials |
| NCT02441972 | Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics | unknown | Phase 1 | 200 | Wuxi No. 4 People's HospitalOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT02804100 | Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients | unknown | — | 200 | Wenzhou Medical UniversityOTHER | 1 | Nov 1, 2016 | clinicaltrials |
| NCT02877043 | Study of the Quality of Lung Resection(ResPul) | unknown | — | 72,000 | Centre Hospitalier Universitaire DijonOTHER | 1 | Aug 24, 2016 | clinicaltrials |
| NCT02270853 | SAS in Patients With Bronchial Carcinoma(SAS CA) | unknown | N/A | 100 | RWTH Aachen UniversityOTHER | 1 | Feb 18, 2016 | clinicaltrials |
| NCT02648087 | Prevalence of Sleep-disordered Breathing in Patients With a Newly Diagnosed Non Small Cell Lung Cancer(NEOSAS) | unknown | N/A | 1,200 | University Hospital, AngersOTHER_GOV | 0 | Jan 6, 2016 | clinicaltrials |
| NCT01058785 | Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer | completed | Phase 2 | 75 | NovaRx CorporationINDUSTRY | 1 | Jul 29, 2010 | clinicaltrials |
| NCT00102505 | A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 36 | Pharmacyclics LLC.INDUSTRY | 1 | Apr 3, 2009 | clinicaltrials |
| NCT00196885 | Effect of an Antioxidant on Cancer-Cachectic Patients Undergoing Exercise Training | completed | Phase 2 | 60 | German Cancer Research CenterOTHER | 1 | Jun 20, 2008 | clinicaltrials |
| NCT00001515 | Diagnostic Effectiveness of Virtual Bronchoscopy | completed | Phase 1 | 120 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00407264 | Randomized Trial of Fluticasone in Bronchial Premalignancy | completed | Phase 2 | 90 | Amsterdam UMC, location VUmcOTHER | 1 | Dec 4, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Aug 18, 2026source: clinicaltrials